1. Poland Stocks

  2. •

    Consumer non-durables

  3. •

    Household/Personal care
Pharmena S.A.

Pharmena S.A.

GGPW:PHR
2.99
PLN
0.00
(0.00%)
-0.27EPS
35.08MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.54
1.53
1.9
1.73
1.42
1.48
1.11
0.9
1.37
1.71
0.11
- -
0.14
0.13
Basic EPS, GAAP
-0.31
-0.44
-0.39
-0.18
-0.28
-0.05
-0.94
-0.63
-0.41
-0.14
-1.42
- -
-0.25
-0.27
Free Cash Flow per Basic Share
-0.42
-0.64
-0.47
-0.12
0.08
0.41
-1.34
-0.22
-0.32
0.14
2.65
- -
-0.32
-0.31
Dividend per Share
0.1
0.11
0.11
0.11
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.96
1.42
0.94
0.65
0.26
0.22
0.47
-0.01
-0.44
-0.58
2.11
- -
0.87
0.73
Tangible Book Value per Share
1.79
1.3
0.86
0.56
0.16
0.08
0.37
-0.1
-0.52
-0.67
2.01
- -
0.74
0.58
Basic Weighted Avg Shares
9
9
9
9
9
9
10
11
11
11
11
11
11
11
Sales/Revenue/Turnover
14
14
17
16
12
13
11
10
15
19
1
- -
2
1
Operating Margin (%)
-9.51
-26.91
-16.27
-7.18
-17.83
0.62
-92.3
-60.76
-26.45
-2.57
-249
- -
-207.42
-227.99
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
1
1
- -
- -
- -
- -
Net Income, GAAP
-3
-4
-4
-2
-2
- -
-9
-7
-5
-2
-16
- -
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-20.11
-28.92
-20.71
-10.46
-19.68
-3.4
-84.96
-69.37
-30.18
-8.25
-1,268.27
- -
-175.59
-209.24
Working Capital
16
11
7
5
1
- -
2
-3
-3
-7
22
- -
8
6
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
18
13
9
6
2
2
5
- -
-5
-7
23
- -
10
8
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-21.04
-26.25
-33.24
-22.77
-58.71
-20.33
-266.65
- -
- -
- -
- -
- -
- -
-31.51

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
29
37
35

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9
8
7
Cash, Cash Equivalents & STI
8
7
6
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
-0.08
-0.04
- -
- -
2025
-0.04
-0.06
-0.06
-0.08
-0.25
2026
-0.04
-0.09
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Konrad Palka
Full Time Employees
7
Sector
Consumer non-durables
Industry
Household/Personal care
Address
Gdanska 47/49 Lodz LDZ Poland 90-729
IPO Date
Aug 25, 2008
Website
pharmena.eu
Similar Companies
Procter & Gamble Company (The) (NYSE:PG)
Cupid Limited (NSE:CUPID)
Hindustan Unilever Limited (NSE:HINDUNILVR)
Colgate-Palmolive (India) Limited (NSE:COLPAL)
Dabur India Limited (NSE:DABUR)
e.l.f. Beauty, Inc. (NYSE:ELF)
Business
Pharmena S.A. Pharmena S.A. (PHR.WA) is a Poland-based biotechnology company that develops, manufactures and commercializes innovative cosmeceuticals, pharmaceuticals and dietary supplements based on its proprietary patented active ingredient 1-MNA (1-methylnicotinamide); core product lines include Dermena for hair loss prevention and treatment, Menavitin dietary supplements targeting cardiovascular health by stimulating prostacyclin production and reducing atherosclerosis risk, Allerco for skin allergies and moderate acne, and Thermi for sunburns, anti-aging, dandruff and body care such as shampoos, conditioners, lotions, tonics and gels. The company operates primarily in Poland with international distribution of active ingredients for medicines and private label production, conducts multidirectional research in dermatology, cardiovascular diseases and lifestyle-related disorders including clinical studies in the United States and Canada, and maintains a diversified portfolio addressing excessive hair loss, skin regeneration, allergies and preventive healthcare. Founded in 2002 and headquartered in Lódz at Gdanska 47/49, Pharmena S.A. focuses on natural physiological solutions protected by over 85 patents in Europe and North America, employs seven people under CEO Konrad Palka, and continues advancing oral medicines for cardiovascular applications while recently emphasizing commercialization of its Menavitin supplement line as a key innovation for elderly consumers to supplement declining natural 1-MNA levels.